A new phase 2/3 will enrol a broad second-line EGFR-mutant NSCLC population.
ApexOnco Front Page
Recent articles
The company is to test its KLK2-targeting pasritamig in a late-line setting.
The group’s latest update focused on new data with the KRAS G12C inhibitor elironrasib.
Dellphi-312, testing Imdelltra plus PD-(L)1, will start mid-year.
Final survival analysis draws a blank, and Lantheus throws in the towel.
Conference activity picks up, with the big one – ASCO – at the end of the month.
New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
Three off-the-shelf mRNA therapies join intismeran autogene.
